Pfizer, Germany’s BioNTech release new data on Covid-19 vaccine
The companies also said their Phase II/III study, slated to enroll about 30,000 participants, had already dosed more than 11,000.
Pfizer, BioNTech start late-stage study of Covid-19 vaccine
The companies said they had started a Phase II/III trial BNT162b2. The news comes the day after Moderna announced the launch of its Phase III study and days after Pfizer and BioNTech signed a nearly $2 billion vaccine supply deal with the federal government.
presented by
Simplify Salon & Spa Employee Management with Meevo’s Comprehensive Software
Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth.